Patients with hematological malignancies have lower CD8+ T cell responses compared to those with solid tumors when infected with SARS-CoV-2 [19,40], although robust CD4+ T cell responses can still be relevant in viral clearance with a predominant CD4+ immunophenotype [21]. This evidence concerns the gene CD8A and hematologic disorder.